New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

America ’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases, including cancer, rare diseases and autoimmune conditions. These advancements are due to the productivity of the United States ’biomedical R&D ecosystem, which is sustained by a policy framework that is designed to support and advance America ’s leadership in the innovation of new medicines.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Research and Development Intellectual Property & D Focus Source Type: news